The fabry disease treatment market consists of revenues earned by entities by providing services such as diagnosis and screening, enzyme replacement therapy, gene therapy, disease management programs, and patient education and support. The market value includes the value of related goods sold by the service provider or included within the service offering. The Fabry disease treatment market also includes sales of Agalsidase alfa, Agalsidase beta, and Migalastat. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
Sizing and Forecast
The fabry disease treatment market size has grown strongly in recent years. It will grow from $1.92 billion in 2023 to $2.09 billion in 2024 at a compound annual growth rate (CAGR) of 8.8%. The growth in the historic period can be attributed to increasing awareness and diagnosis rates, increasing adoption of enzyme replacement therapies, increasing use of chaperone therapies, increasing healthcare infrastructure, rise in investment in rare disease research, increasing population, and increasing regulatory incentives for orphan drugs.
The fabry disease treatment market size is expected to see strong growth in the next few years. It will grow to $2.94 billion in 2028 at a compound annual growth rate (CAGR) of 8.9%. The growth in the forecast period can be attributed to increasing prevalence of the disease, rising awareness and diagnosis rates, expanding healthcare infrastructure, growing investment in rare disease research, growing patient awareness, and expanding reimbursement policies. Major trends in the forecast period include advancements in gene therapy, advancements in enzyme replacement therapies, advancements in diagnostic techniques, advancements in novel therapies, and integration of digital health technologies for patient management.
Order your report now for swift delivery, visit the link:
https://www.thebusinessresearchcompany.com/report/fabry-disease-treatment-global-market-report
Segmentation & Regional Insights
The fabry disease treatment market covered in this report is segmented –
1) By Treatment: Substrate Reduction Therapy, Enzyme Replacement Therapy, Chaperone Treatment, Other Treatments
2) By Route Of Administration: Oral Route, Intravenous Route
3) By Disease Severity: Classic Fabry Disease, Late-Onset Fabry Disease
4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
North America was the largest region in the fabry disease treatment market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the fabry disease treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Intrigued to explore the contents? Secure your hands-on a free sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=16421&type=smp
Major Driver Impacting Market Growth
The increasing prevalence of renal diseases is expected to propel the growth of the fabry disease treatment market going forward. Renal diseases, also known as kidney diseases, refer to any conditions impairing the kidneys’ function. The cases of renal diseases are growing due to genetic predispositions, lifestyle choices, environmental factors, and underlying health conditions. Fabry disease is caused by the accumulation of globotriaosylceramide (Gb3) in kidney cells, leading to damage and dysfunction, highlighting the critical need for early detection and intervention to prevent kidney complications. For instance, in December 2023, the Australian Bureau of Statistics, an Australian government agency, reported that 246,200 people (1.0% of the population) had kidney disease in 2022, representing a 0.2% increase over the past decade. Therefore, the increasing prevalence of renal diseases is driving the growth of the fabry disease treatment market.
Key Industry Players
Major companies operating in the fabry disease treatment market are Sanofi S.A., GSK plc, Takeda Pharmaceutical Company Limited, CHIESI Farmaceutici S.p.A., Ultragenyx Pharmaceutical Inc., Amicus Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Sangamo Therapeutics Inc., Idorsia Pharmaceuticals Ltd., Centogene N.V., Protalix BioTherapeutics, Avrobio Inc., ISU Abxis, Synageva BioPharma Corp., Greenovation Biotech GmbH, CANbridge Pharmaceuticals, Freeline, 4D Molecular Therapeutics, Abeona Therapeutics Inc., GC Biopharma Corporation
The fabry disease treatment market report table of contents includes:
1. Executive Summary
- Fabry Disease Treatment Market Characteristics
- Fabry Disease Treatment Market Trends And Strategies
- Fabry Disease Treatment Market – Macro Economic Scenario
- Global Fabry Disease Treatment Market Size and Growth
.
32. Global Fabry Disease Treatment Market Competitive Benchmarking - Global Fabry Disease Treatment Market Competitive Dashboard
- Key Mergers And Acquisitions In The Fabry Disease Treatment Market
- Fabry Disease Treatment Market Future Outlook and Potential Analysis
- Appendix
Explore the trending research reports from TBRC
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
